1. Home
  2. SMX vs CTXR Comparison

SMX vs CTXR Comparison

Compare SMX & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SMX (Security Matters) Public Limited Company

SMX

SMX (Security Matters) Public Limited Company

HOLD

Current Price

$16.61

Market Cap

18.8M

Sector

Technology

ML Signal

HOLD

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

HOLD

Current Price

$0.60

Market Cap

18.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMX
CTXR
Founded
N/A
2007
Country
Ireland
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.8M
18.7M
IPO Year
2022
2010

Fundamental Metrics

Financial Performance
Metric
SMX
CTXR
Price
$16.61
$0.60
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
12.5K
982.8K
Earning Date
04-23-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
43.38
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$147.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.75
$0.47
52 Week High
$490.00
$2.19

Technical Indicators

Market Signals
Indicator
SMX
CTXR
Relative Strength Index (RSI) 52.88 50.44
Support Level $14.79 $0.51
Resistance Level $17.75 $0.76
Average True Range (ATR) 1.13 0.06
MACD 0.08 -0.01
Stochastic Oscillator 56.36 29.57

Price Performance

Historical Comparison
SMX
CTXR

About SMX SMX (Security Matters) Public Limited Company

SMX (Security Matters) PLC provides one solution to solve both authentication and track and trace challenges in order to uphold supply chain integrity and provide quality assurance and brand accountability to producers of goods. Its technology works as a track and trace system using a marker, a reader, and an algorithm to identify embedded sub-molecular particles in order to track and trace different components along a production process (or any other marked good along a supply chain) to the end producer.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Share on Social Networks: